scholarly journals Acute Hyperglycemia and Spatial Working Memory in Adolescents With Type 1 Diabetes

Diabetes Care ◽  
2020 ◽  
Vol 43 (8) ◽  
pp. 1941-1944 ◽  
Author(s):  
Jasna Šuput Omladič ◽  
Anka Slana Ozimič ◽  
Andrej Vovk ◽  
Dušan Šuput ◽  
Grega Repovš ◽  
...  
2020 ◽  
Author(s):  
Jasna Šuput Omladič ◽  
Anka Slana Ozimič ◽  
Andrej Vovk ◽  
Dušan Šuput ◽  
Grega Repovš ◽  
...  

<i>Objective:</i> <a>To investigate the effect of acute hyperglycemia on brain function in adolescents with type 1 diabetes.</a> <p><i><br></i></p><p><i>Research Design and Methods:</i><b> </b>Twenty participants with type 1 diabetes (T1D) (age 14.64 ±1.78 years) and 20 age-matched healthy controls (age 14.40± 2.82 years) performed two functional magnetic resonance imaging sessions. Participants with T1D performed the first scanning session under euglycemic and the second under hyperglycemic clamp (20 mmol/L (360 mg/dL)).<b> </b></p> <p><i><br></i></p><p><i>Results:</i> Lower spatial working memory (sWM) capacity during acute hyperglycemia and significant differences in activation of regions of interest during different stages of the spatial working memory task (p=0.014) were observed.<b> </b><b></b></p> <p><i><br></i></p><p><i>Conclusions</i>: Acute hyperglycemia negatively affected sWM capacity in adolescents with T1D, which is relevant for daily functioning and academic performance.</p>


2020 ◽  
Author(s):  
Jasna Šuput Omladič ◽  
Anka Slana Ozimič ◽  
Andrej Vovk ◽  
Dušan Šuput ◽  
Grega Repovš ◽  
...  

<i>Objective:</i> <a>To investigate the effect of acute hyperglycemia on brain function in adolescents with type 1 diabetes.</a> <p><i><br></i></p><p><i>Research Design and Methods:</i><b> </b>Twenty participants with type 1 diabetes (T1D) (age 14.64 ±1.78 years) and 20 age-matched healthy controls (age 14.40± 2.82 years) performed two functional magnetic resonance imaging sessions. Participants with T1D performed the first scanning session under euglycemic and the second under hyperglycemic clamp (20 mmol/L (360 mg/dL)).<b> </b></p> <p><i><br></i></p><p><i>Results:</i> Lower spatial working memory (sWM) capacity during acute hyperglycemia and significant differences in activation of regions of interest during different stages of the spatial working memory task (p=0.014) were observed.<b> </b><b></b></p> <p><i><br></i></p><p><i>Conclusions</i>: Acute hyperglycemia negatively affected sWM capacity in adolescents with T1D, which is relevant for daily functioning and academic performance.</p>


2021 ◽  
Author(s):  
Geisa B. Gallardo‐Moreno ◽  
Francisco J. Alvarado‐Rodríguez ◽  
Rebeca Romo‐Vázquez ◽  
Hugo Vélez‐Pérez ◽  
Andrés A. González‐Garrido

PLoS ONE ◽  
2017 ◽  
Vol 12 (6) ◽  
pp. e0178172 ◽  
Author(s):  
Joan Guàrdia-Olmos ◽  
Geisa B. Gallardo-Moreno ◽  
Esteve Gudayol-Ferré ◽  
Maribel Peró-Cebollero ◽  
Andrés A. González-Garrido

Diabetologia ◽  
2017 ◽  
Vol 61 (3) ◽  
pp. 551-561 ◽  
Author(s):  
Michael Gejl ◽  
Albert Gjedde ◽  
Birgitte Brock ◽  
Arne Møller ◽  
Eelco van Duinkerken ◽  
...  

2018 ◽  
Vol 32 (2) ◽  
pp. 234-239 ◽  
Author(s):  
Brian C. Bucca ◽  
David M. Maahs ◽  
Janet K. Snell-Bergeon ◽  
John Hokanson ◽  
Sean Rinella ◽  
...  

2014 ◽  
Vol 16 (1) ◽  
pp. 56-62 ◽  
Author(s):  
Mohammad Yousef ◽  
Anton Westman ◽  
Ann Lindberg ◽  
Cecilia de Lacerda ◽  
Johan Jendle

Diabetes Care ◽  
2003 ◽  
Vol 26 (2) ◽  
pp. 390-396 ◽  
Author(s):  
A. J. Sommerfield ◽  
I. J. Deary ◽  
V. McAulay ◽  
B. M. Frier

Diabetes ◽  
2020 ◽  
Vol 69 (8) ◽  
pp. 1770-1778
Author(s):  
Lara C. Foland-Ross ◽  
Gabby Tong ◽  
Nelly Mauras ◽  
Allison Cato ◽  
Tandy Aye ◽  
...  

BMJ Open ◽  
2018 ◽  
Vol 8 (8) ◽  
pp. e021800 ◽  
Author(s):  
Natalie A Pride ◽  
Belinda Barton ◽  
Paul Hutchins ◽  
David R Coghill ◽  
Mayuresh S Korgaonkar ◽  
...  

IntroductionDopamine dysregulation has been identified as a key modulator of behavioural impairment in neurofibromatosis type 1 (NF1) and a potential therapeutic target. Preclinical research demonstrates reduced dopamine in the brains of genetically engineered NF1 mouse strains is associated with reduced spatial-learning and attentional dysfunction. Methylphenidate, a stimulant medication that increases dopaminergic and noradrenergic neurotransmission, rescued the behavioural and dopamine abnormalities. Although preliminary clinical trials have demonstrated that methylphenidate is effective in treating attention deficit hyperactivity disorder (ADHD) symptoms in children with NF1, its therapeutic effect on cognitive performance is unclear. The primary aim of this clinical trial is to assess the efficacy of methylphenidate for reducing attention deficits, spatial working memory impairments and ADHD symptoms in children with NF1.Methods and analysisA randomised, double-blind, placebo-controlled trial of methylphenidate with a two period crossover design. Thirty-six participants with NF1 aged 7–16 years will be randomised to one of two treatment sequences: 6 weeks of methylphenidate followed by 6 weeks of placebo or; 6 weeks of placebo followed by 6 weeks of methylphenidate. Neurocognitive and behavioural outcomes as well as neuroimaging measures will be completed at baseline and repeated at the end of each treatment condition (week 6, week 12). Primary outcome measures are omission errors on the Conners Continuous Performance Test-II (attention), between-search errors on the Spatial Working Memory task from the Cambridge Neuropsychological Test Automated Battery (spatial working memory) and the Inattentive and Hyperactivity/Impulsivity Symptom Scales on the Conners 3-Parent. Secondary outcomes will examine the effect of methylphenidate on executive functions, attention, visuospatial skills, behaviour, fine-motor skills, language, social skills and quality of life.Ethics and disseminationThis trial has hospital ethics approval and the results will be disseminated through peer-reviewed publications and international conferences.Trial registration numberACTRN12611000765921.


Sign in / Sign up

Export Citation Format

Share Document